All translations
Jump to navigation
Jump to search
Enter a message name below to show all available translations.
Found 2 translations.
| Name | Current message text |
|---|---|
| h English (en) | ==GLP-1, GIP, and glucagon receptor triple agonists== Following the discovery of GLP-1/GIP and GLP-1/glucagon dual agonists, it was hoped that a triple agonist would provide additive or synergistic metabolic benefits. A clinical trial of the triple agonist [[retatrutide]] found an average −24.2 percent weight reduction in the highest dosage group after 24 weeks. |
| h Japanese (ja) | ==GLP-1、GIPおよびグルカゴン受容体トリプルアゴニスト== {{Anchor|GLP-1, GIP, and glucagon receptor triple agonists}} GLP-1/GIPおよびGLP-1/グルカゴンのデュアルアゴニストが発見された後、トリプルアゴニストが相加的または相乗的な代謝効果をもたらすことが期待された。トリプルアゴニスト[[retatrutide/ja|retatrutide]]の臨床試験では、24週間後に最高用量群で平均-24.2％の体重減少が見られた。 |